<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661709</url>
  </required_header>
  <id_info>
    <org_study_id>Wenxin granule-20201122</org_study_id>
    <nct_id>NCT04661709</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris</brief_title>
  <official_title>Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Special Project of National Traditional Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized placebo-controlled trial which aims to evaluate the&#xD;
      efficacy and safety of Wen Xin granule in patients with unstable angina pectoris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary heart disease has remained the leading cause of death worldwide over the past&#xD;
      decades. Unstable angina is a clinical syndrome intermediate in severity between stable&#xD;
      angina and acute myocardial infarction with high morbidity and mortality. Standard drug&#xD;
      therapy and invasive revascularization are effective in decreasing progression to infarction,&#xD;
      reducing symptoms and multiple hospitalizations, in most cases without a decrease in the&#xD;
      long-term mortality rate. However, there are still many patients with persistence or&#xD;
      recurrence of angina despite standard medical therapy and/or revascularization. Wen Xin&#xD;
      granule, as a Chinese herbal medicine has shown great effect in patients with unstable angina&#xD;
      in our clinical. However, there is still insufficient evidence on his specific efficacy and&#xD;
      safety. Therefor, we'd like to evaluate the efficacy and safety of Wen Xin granule in&#xD;
      patients with unstable angina through this multi-center, double-blind, randomized&#xD;
      placebo-controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>It's a double-blind trial and includes two levels of blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>Record the incidence of major adverse cardiovascular events in one year by follow-up.</time_frame>
    <description>Including recurrent angina, acute myocardial infarction, severe arrhythmia, heart failure, and cardiac death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The thrombelastograph</measure>
    <time_frame>Before treatment and at eight weeks after treatment.</time_frame>
    <description>Parameters assessed by were R (represent clotting time), K and Angle (reflect clot strength and development), MA (maximum platelet-fibrin clot strength), CI (represents overall coagulability), and LY30 (represents lysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCM symptom scale score</measure>
    <time_frame>Before treatment, four and eight weeks after treatment.</time_frame>
    <description>TCM syndrome scale includes items of chest tightness, chest pain, heavy body, obesity, phlegm, dark complexion, tongue condition and pulse condition. The chest tightness and chest pain, have 4-grade options of none, mild, moderate and severe, marked as 0, 2, 4 and 6 respectively. The other items have two options of yes or no, marked as 0 and 1 respectively. The higher scores mean more serious symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seattle angina questionnaire</measure>
    <time_frame>Before treatment, four and eight weeks after treatment.</time_frame>
    <description>The SAQ regroups 19 items measuring five specific scales: physical limitations, anginal stability, anginal frequency, treatment satisfaction and disease perception targeting a specific disease and treatment group. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">502</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Unstable Angina</condition>
  <condition>Chinese Herbal Medicine</condition>
  <arm_group>
    <arm_group_label>Wen Xin granule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are given Wen Xin granule by mouth, one dose daily for 2 months &amp; Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients are given Wen Xin granule placebo by mouth, one dose daily for 2 months &amp; Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartrate Tab 25mg, Trimetazidine Dihydrochloride Tablets 20mg tid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wen Xin granule</intervention_name>
    <description>one dose daily, two times per day.</description>
    <arm_group_label>Wen Xin granule</arm_group_label>
    <other_name>WXG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet</intervention_name>
    <description>one tablet daily. (for patients who can't use aspirin)</description>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_label>Wen Xin granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium</intervention_name>
    <description>20 mg tablet, one tablet each night.</description>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_label>Wen Xin granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate Tab 20 MG</intervention_name>
    <description>one tabletï¼Œ twice daily.</description>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_label>Wen Xin granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Tartrate Tab 25 MG</intervention_name>
    <description>12.5 mg or 25 mg, two times daily.</description>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_label>Wen Xin granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Enteric-coated Tablets</intervention_name>
    <description>100mg tablet, one tablet daily.</description>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_label>Wen Xin granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WXG placebo</intervention_name>
    <description>one dose daily, two times per day.</description>
    <arm_group_label>WXG placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimetazidine Dihydrochloride Tablets</intervention_name>
    <description>20 mg tablet, one tablet three times daily.</description>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_label>Wen Xin granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glyceryl trinitrate</intervention_name>
    <description>be taken when angina pectoris attacks.</description>
    <arm_group_label>WXG placebo</arm_group_label>
    <arm_group_label>Wen Xin granule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged between 35 and 75 years of age;&#xD;
&#xD;
          -  diagnosed with CAD through coronary arteriography, clinically diagnosed with UAP in&#xD;
             low or medium risk;&#xD;
&#xD;
          -  belong to Yang deficiency and blood stasis syndrome according to TCM, and give written&#xD;
             informed consent.&#xD;
&#xD;
          -  For the diagnostic criteria of UAP, the investigators will refer to 2014 AHA/ACC&#xD;
             Guidelines for the Diagnosis and Management of Non-ST-Elevation Acute Coronary&#xD;
             Syndromes.&#xD;
&#xD;
          -  For the TCM diagnostic criteria, the investigators will refer to Guidelines for&#xD;
             Clinical Research into New Traditional Chinese Medicine Drugs for Chest Obstruction&#xD;
             (2002 edition).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chest pain caused by congenital heart diseases, valvular heart disease, severe&#xD;
             neurosis, or arrhythmia&#xD;
&#xD;
          -  with New York Heart Association class III or IV heart failure, in acute phase of&#xD;
             cerebral infarction;&#xD;
&#xD;
          -  with uncontrolled hypertension (systolic blood pressure &gt;160 mmHg and/or diastolic&#xD;
             blood pressure &gt;95 mmHg in the resting state)&#xD;
&#xD;
          -  with uncontrolled hyperglycemia or diabetic complications, with mental and&#xD;
             neurological abnormalities or dysgnosia;&#xD;
&#xD;
          -  female patients in pregnancy or lactation;&#xD;
&#xD;
          -  by participating in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, M.D.</last_name>
    <phone>+86 13051458913</phone>
    <email>gamyylj@163.com</email>
  </overall_contact>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <reference>
    <citation>Niccoli G, Montone RA, Lanza GA, Crea F. Angina after percutaneous coronary intervention: The need for precision medicine. Int J Cardiol. 2017 Dec 1;248:14-19. doi: 10.1016/j.ijcard.2017.07.105. Epub 2017 Aug 12. Review.</citation>
    <PMID>28807510</PMID>
  </reference>
  <reference>
    <citation>Ambrose JA, Dangas G. Unstable angina: current concepts of pathogenesis and treatment. Arch Intern Med. 2000 Jan 10;160(1):25-37. Review.</citation>
    <PMID>10632302</PMID>
  </reference>
  <reference>
    <citation>Smith JN, Negrelli JM, Manek MB, Hawes EM, Viera AJ. Diagnosis and management of acute coronary syndrome: an evidence-based update. J Am Board Fam Med. 2015 Mar-Apr;28(2):283-93. doi: 10.3122/jabfm.2015.02.140189. Review.</citation>
    <PMID>25748771</PMID>
  </reference>
  <results_reference>
    <citation>Jiang M, Zhang C, Zheng G, Guo H, Li L, Yang J, Lu C, Jia W, Lu A. Traditional chinese medicine zheng in the era of evidence-based medicine: a literature analysis. Evid Based Complement Alternat Med. 2012;2012:409568. doi: 10.1155/2012/409568. Epub 2012 Jun 6.</citation>
    <PMID>22719784</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang HJ, Wang ZX. Yin-yang and Zheng: Exported from Chinese medicine. Chin J Integr Med. 2014 Apr;20(4):250-5. doi: 10.1007/s11655-014-1777-z. Epub 2014 Apr 3.</citation>
    <PMID>26972437</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun Li</investigator_full_name>
    <investigator_title>Director of cardiovascular department of Guang'anmen Hospital.</investigator_title>
  </responsible_party>
  <keyword>coronary heart disease</keyword>
  <keyword>unstable angina</keyword>
  <keyword>Chinese herbal medicine</keyword>
  <keyword>Wen Xin granule</keyword>
  <keyword>traditional Chinese medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Trimetazidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

